Immune Rejuvenation Jab Heads to Human Trials

Is this a promising breakthrough against aging or will it be another mouse-to-human disappointment?

Published JUN 20

Immune Rejuvenation Jab Heads to Human Trials

Story

Above: An elderly person receives a flu vaccination in Hong Kong, China, on Nov. 7, 2005. Image credit: MN Chan/Getty Images

The Facts

A first-in-human clinical trial of an experimental immune rejuvenation jab is expected to begin later this year, with up to 50 adult participants initially selected from those with immune dysfunction, including chronic viral infections such as HIV.
UCL News
The Sun
The Independent
The therapy, developed by U.K. biotech company SenTcell and founded by Dr. Alessio Lanna of University College London, targets worn-out CD4+ T cells — often called the "conductors" of the immune system — which become less effective with age and chronic disease.
The Independent
GB News
The treatment is a liquid formulation delivered by intramuscular injection, designed to reprogram pathways that drive immune dysfunction and help immune cells regain characteristics of younger, healthier cells.
News Medical
Female First
Animal studies reported lifespan increases of up to five years in rodents, which researchers say is equivalent to around 40 to 50 additional years for humans. Dr. Lanna noted the animals "lived to the equivalent of 120 human years."
Female First
The Sun
Previous laboratory studies suggest that rejuvenated CD4+ T cells may release telomere-containing structures — termed "telomere Rivers" by researchers — into the bloodstream, though this has not yet been demonstrated in humans.
The Independent
News Medical
The research program has received support through the MHRA's Innovative Licensing and Access Pathway. Dr. Lanna described the trial as "an important step towards testing whether we can safely rejuvenate exhausted immune cells and restore aspects of healthy immune function."
GB News
UCL News

Sources Split

LEFT

CENTER

RIGHT

ESTAB
CRIT

CENTER

PRO
ESTAB

The Spin

Techno-optimist narrative

This new jab could genuinely reverse immune aging and help the body fight off cancer, HIV and dementia. The treatment targets worn-out T-cells, restoring the immune system's ability to recognize threats the way it did in youth. Early animal results have been impressive enough to spark serious optimism, with lifespan gains that would roughly translate to decades in human terms. With the first human trial set to begin this year, this approach could open an entirely new chapter in how we think about aging and disease.

The Sun

The Independent

Techno-skeptic narrative

Anti-aging immune treatments have dazzled in mice for decades but consistently stumble when tested in humans, and the pattern of hype followed by disappointment is well established in this field. Senescent cell research still lacks standardized biomarkers, large-scale clinical validation and long-term safety data. Clearing worn-out cells also risks eliminating ones that serve vital functions like wound healing, making caution the only responsible posture.